Massachusetts AI and Technology Center for Connected Care in Aging and Alzheimer's Disease (MAITC): Clinical Translation and Validation Core

马萨诸塞州老龄化和阿尔茨海默病互联护理人工智能和技术中心 (MAITC)：临床转化和验证核心

• 批准号: 10274692
• 负责人: Deepak Ganesan
• 金额: $ 24.82万
• 依托单位: UNIVERSITY OF MASSACHUSETTS AMHERST
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10274692
• 关键词: Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; Biological Sciences; Brain; Caring; Clinical; Cohort Studies; Consult; Consultations; Data Analytics; Databases; Elderly; Enhancement Technology; Home; Hospitals; Individual; Institutes; Longitudinal cohort study; Massachusetts; Monitor; Patient Recruitments; Pilot Projects; Process; Research; Research Design; Research Personnel; Research Project Grants; Resources; Services; Technology; Training; Translations; Validation; Woman; analytical method; base; clinical translation; cohort; connected care; design; feasibility testing; healthy aging; improved; interest; knowledge base; older patient; programs; recruit; research to practice; rural setting; success; technology validation; urban setting; usability

PROJECT SUMMARY: Clinical Translation & Validation Core The activities of the Clinical Translation and Validation Core will support the pilot project research process for the Massachusetts AI and Technology Center for Connected Care in Aging and Alzheimer's Disease (MAITC) by providing access to state-of-art facilities, consulting services, and intellectual resources to enable validation and feasibility-testing of AI-enhanced technologies. To achieve these objectives, the Clinical Translation and Validation Core will pursue the following three aims. First, it will provide a streamlined validation pipeline for taking promising AI-enhanced technologies from benchtop to real-world deployment to enable at-home use for older adults and patients with AD/ADRD. To accomplish this, the Clinical Translation and Validation Core will leverage state-of-art facilities for technology validation at the UMass Amherst Institute of Applied Life Sciences (IALS) and the Northeastern Consortium on Technology for Proactive Care. The Clinical Translation and Validation Core will also provide pilot project teams the opportunity to recruit participants in both urban and rural settings across Eastern and Western Massachusetts. The Clinical Translation and Validation Core will leverage longitudinal study cohorts already engaged with the Massachusetts Alzheimer’s Disease Research Center (MADRC) and the Harvard Brain Study (HABS), and ad-hoc cohorts at the Brandeis and Brigham Women’s Hospital Roybal Centers and UMass IALS. Second, the Clinical Translation and Validation Core will support the pilot project process by contributing to defining the call for proposals by suggesting AI-enhanced technologies that are suitable for validation by leveraging MIATC resources (in coordination with the Technology Identification and Training Core). It will also provide input regarding the selection of pilots based on technical, usability, and feasibility criteria and offer consulting services and technical support to enhance likelihood of pilot project success. Third, the Clinical Translation and Validation Core will maintain a continually evolving knowledge base of emerging advances in AI-enhanced technologies that have the potential to significantly improve Healthy Aging and AD/ADRD care. This database will summarize the key strengths and weaknesses of these technologies and the types of settings where each technology could be used. The Clinical Translation and Validation Core will also facilitate pairing of technology developers with clinical researchers and other stakeholders with interest in validating AI-enhanced technologies. The activities of the Clinical Translation and Validation Core will increase the impact of the pilot project program by providing teams with resources to bridge the gap between research and implementation in real-world settings.

项目概要：临床翻译和验证核心 临床翻译和验证核心的活动将支持试点项目研究过程， 马萨诸塞州老龄化和阿尔茨海默病互联护理人工智能和技术中心（MAITC） 通过提供最先进的设施、咨询服务和智力资源， 以及人工智能增强技术的可行性测试。 为了实现这些目标，临床翻译和验证核心将追求以下三个目标。 首先，它将提供一个简化的验证管道，用于将有前途的AI增强技术从 从台式到实际部署，使老年人和AD/ADRD患者能够在家中使用。到 为了实现这一目标，临床翻译和验证核心将利用最先进的技术设施， 验证在马萨诸塞大学阿默斯特应用生命科学研究所（IALS）和东北联盟， 主动护理技术。临床翻译和验证核心还将提供试点项目 团队有机会在东部和西部的城市和农村环境中招募参与者 马萨诸塞州。临床翻译和验证核心将利用纵向研究队列， 与马萨诸塞州阿尔茨海默氏症研究中心（MADRC）和哈佛大脑研究中心合作 研究（HABS），以及Brandeis和Brigham妇女医院Roybal中心的特设队列， 麻省大学IALS。其次，临床翻译和验证核心将通过以下方式支持试点项目流程： 通过提出适合于以下方面的人工智能增强技术，为定义提案呼吁做出贡献： 通过利用MIATC资源进行验证（与技术鉴定和培训协调 核心）。它还将根据技术、可用性和可行性提供关于选择试点的输入 标准，并提供咨询服务和技术支持，以提高试点项目成功的可能性。第三、 临床翻译和验证核心将保持不断发展的知识基础， 人工智能增强技术的进步，有可能显着改善健康老龄化， AD/ADRD护理。该数据库将总结这些技术的主要优点和缺点， 每种技术可以使用的环境类型。临床翻译和验证核心将 还促进技术开发人员与临床研究人员和其他利益相关者的配对， 验证AI增强技术。临床翻译和验证核心的活动将增加 通过为团队提供资源，弥合研究之间的差距， 并在现实世界中实现。